Compare NFJ & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFJ | MNKD |
|---|---|---|
| Founded | 2005 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2003 | 2004 |
| Metric | NFJ | MNKD |
|---|---|---|
| Price | $14.23 | $3.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.08 |
| AVG Volume (30 Days) | 332.8K | ★ 3.3M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 9.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $26.63 |
| Revenue Next Year | N/A | $14.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $12.25 | $2.23 |
| 52 Week High | $15.75 | $6.51 |
| Indicator | NFJ | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 61.07 |
| Support Level | $14.14 | $3.24 |
| Resistance Level | $15.20 | $4.28 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | -0.03 | 0.08 |
| Stochastic Oscillator | 10.46 | 95.65 |
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.